Share

Save

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

RECRUITING

Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system.

info
Simpliy with AI

Study details:

Study to assess the feasibility, safety, and performance of the HighLife CLARITY TSMV, and its deliver systems, in NYHA Class ≥ II-IV patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment according to the local multidisciplinary Heart Team decision, and who are at high risk for potential LVOT obstruction(LVOTO).

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Age ≥ 18 years
  • Moderate-severe or severe mitral regurgitation (≥ 3+)
  • Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV
  • Patient is under guideline directed medical therapy for at least one month, as reviewed and confirmed by the local multidisciplinary Heart Team
  • Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability
  • Patient meets the anatomical criteria for HighLife valve
  • Patient is willing to participate in the study and provides signed informed consent
  • Patients with a high risk for LVOTO
  • Exclusion criteria

  • Any stroke/TIA within 30 days
  • Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)
  • Active infections requiring antibiotic therapy
  • Active ulcer or gastro-intestinal bleeding in the past 3 months
  • History of bleeding diathesis, coagulopathy or refusal of future blood transfusion
  • Patients in whom TEE is not feasible
  • Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.
  • Patient is unable to comply with the follow-up schedule and assessments
  • Participation in another clinical investigation at the time of inclusion
  • Patient has known allergies to the device components or contrast medium
  • Patient cannot tolerate anticoagulation or antiplatelet therapy
  • Patients with a life expectancy of less than 12 months due to non-cardiac conditions
  • Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2021-07-01

    Primary completion: 2025-12-01

    Study completion finish: 2031-02-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      NA

    trial

    Trial ID

    NCT04888247

    Intervention or treatment

    DEVICE: CLARITY

    Conditions

    • Mitral Regurgitation

    Find a site

    Closest Location:

    Wesley Hospital

    Research sites nearby

    Select from list below to view details:

    • Wesley Hospital

      Auchenflower, Not Specified, Australia

    • Mount Hospital

      Perth, Not Specified, Australia

    • Macquarie University Hospital

      Sydney, Not Specified, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Treatment
    • Trans-septal mitral valve replacement
    DEVICE: CLARITY
    • Trans-septal mitral valve replacement

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Rate of subjects meeting Technical Success* Successful vascular access, delivery and retrieval of the HighLife delivery systems * Deployment and correct positioning of the HighLife 28mm CLARITY TSMV * Freedom from additional emergency surgery or re-intervention related to the device or access procedure, that occurred (was initiated) during the procedure. Any emergency surgery or re-intervention that occurs after the patient exits the procedure room/cath lab in stable condition will be captured as an AE/SAE * Successful vascular access, delivery and retrieval of the HighLife delivery systems * Deployment and correct positioning of the HighLife 28mm CLARITY TSMV * Freedom from additional emergency surgery or re-intervention related to the device or access procedure, that occurred (was initiated) during the procedure. Any emergency surgery or re-intervention that occurs after the patient exits the procedure room/cath lab in stable condition will be captured as an AE/SAE24 hours

    Secondary outcome

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

    Other trails to consider

    Top searched conditions